Page last updated: 2024-09-04

atrasentan and Lung Neoplasms

atrasentan has been researched along with Lung Neoplasms in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Feng, KT; Guo, X; Hong, MH; Liang, WJ; Mai, HQ; Mo, HY; Ye, YL; Zeng, ZY; Zhang, CQ	1
Antonia, S; Bepler, G; Boulware, D; Burton, M; Chiappori, AA; Haura, E; Kapoor, R; Lush, R; Neuger, AM; Padilla, B; Rodriguez, FA; Simon, G; Sullivan, DM; Williams, C	1

Trials

1 trial(s) available for atrasentan and Lung Neoplasms

Article	Year
Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Mar-01, Volume: 14, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Endothelin A Receptor Antagonists; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Pyrrolidines; Survival Rate	2008

Article

Year

Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Mar-01, Volume: 14, Issue:5

Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Endothelin A Receptor Antagonists; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Pyrrolidines; Survival Rate

2008

Other Studies

1 other study(ies) available for atrasentan and Lung Neoplasms

Article	Year
Therapeutic targeting of the endothelin a receptor in human nasopharyngeal carcinoma. Cancer science, 2006, Volume: 97, Issue:12 Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Atrasentan; Cell Proliferation; Cisplatin; Disease Models, Animal; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Fluorouracil; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Neoplasms; Pyrrolidines; Receptor, Endothelin A; Receptor, Endothelin B; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2006

Article

Year

Therapeutic targeting of the endothelin a receptor in human nasopharyngeal carcinoma.

Cancer science, 2006, Volume: 97, Issue:12

Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Atrasentan; Cell Proliferation; Cisplatin; Disease Models, Animal; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Fluorouracil; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Neoplasms; Pyrrolidines; Receptor, Endothelin A; Receptor, Endothelin B; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2006